TOKYO, Mar 25, 2025 – (JCN Newswire) – Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of early Alzheimer’s disease (early AD *) has received the Prime Minister’s Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES **).The Technology Management and Innovation Awards was established in 2012 with the aim ofrecognizing outstanding examples of technology management that have produced world-changing innovations…
Read More
